EZH2 was also reported to be highly expressed in breast cancer and prostate cancer [32, 33]; moreover, EZH2 inhibitors have been considered a promising therapy for certain types of tumors [34, 35]. The gene discussed is EZH2; the disease is breast carcinoma.